These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33484033)

  • 1. Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment.
    Kirino S; Tamaki N; Kurosaki M; Inada K; Yamashita K; Sekiguchi S; Hayakawa Y; Osawa L; Higuchi M; Takaura K; Maeyashiki C; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Izumi N
    J Viral Hepat; 2021 May; 28(5):787-794. PubMed ID: 33484033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China.
    Lou T; Li B; Xiong P; Jin C; Chen Y
    J Viral Hepat; 2021 Oct; 28(10):1373-1380. PubMed ID: 34218498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
    Yip TC; Wong GL; Wong VW; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Chan HL
    J Hepatol; 2020 May; 72(5):847-854. PubMed ID: 31857194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
    Kirino S; Tamaki N; Kaneko S; Kurosaki M; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Maeyashiki C; Yasui Y; Nakanishi H; Tsuchiya K; Itakura J; Takahashi Y; Izumi N
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1595-1601. PubMed ID: 31975419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
    Kim JH; Kim YD; Lee M; Jun BG; Kim TS; Suk KT; Kang SH; Kim MY; Cheon GJ; Kim DJ; Baik SK; Choi DH
    J Hepatol; 2018 Nov; 69(5):1066-1073. PubMed ID: 30075230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 5-year cumulative incidence of HCC development and treatment regimen in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment.
    Wang S; Fang S; Liu Y
    J Viral Hepat; 2021 Sep; 28(9):1333-1334. PubMed ID: 34051028
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessing risk scores for predicting hepatocellular carcinoma in Thai patients with chronic hepatitis B.
    Kamalapirat T; Yingcharoen K; Ungtrakul T; Soonklang K; Dechma J; Chunnuan P; Kusuman P; Pothijaroen C; Tawpa J; Cheirsilpa K; Auewarakul C
    J Viral Hepat; 2021 Jul; 28(7):1034-1041. PubMed ID: 33880807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy.
    Lee HW; Kim SU; Park JY; Kim DY; Ahn SH; Han KH; Kim BK
    Liver Int; 2019 Sep; 39(9):1624-1630. PubMed ID: 31050379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B.
    Voulgaris T; Papatheodoridi M; Lampertico P; Papatheodoridis GV
    Liver Int; 2020 Mar; 40(3):484-495. PubMed ID: 31884726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy.
    Güzelbulut F; Gökçen P; Can G; Adalı G; Değirmenci Saltürk AG; Bahadır Ö; Özdil K; Doğanay HL
    J Viral Hepat; 2021 May; 28(5):826-836. PubMed ID: 33586270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes Mellitus Impacts on the Performance of Hepatocellular Carcinoma Risk Scores in Chronic Hepatitis B Patients.
    Yip TC; Wong VW; Lai MS; Lai JC; Tse YK; Liang LY; Hui VW; Chan HL; Wong GL
    Clin Gastroenterol Hepatol; 2023 Oct; 21(11):2864-2875.e16. PubMed ID: 36828301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
    Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
    Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of liver stiffness enhances the predictive accuracy of the PAGE-B model for hepatitis B-related hepatocellular carcinoma.
    Chon HY; Lee HA; Suh SJ; Lee JI; Kim BS; Kim IH; Lee CH; Jang BK; Lee HW; Hwang JS; Lee CH; Lee JW; Yu JH; Seo YS; Yim HJ; Kim SU;
    Aliment Pharmacol Ther; 2021 Apr; 53(8):919-927. PubMed ID: 33465253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
    Kaneko S; Kurosaki M; Mashiba T; Marusawa H; Kondo M; Kojima Y; Uchida Y; Fujii H; Akahane T; Yagisawa H; Kusakabe A; Kobashi H; Abe T; Yoshida H; Ogawa C; Furuta K; Tamaki N; Tsuji K; Matsushita T; Izumi N;
    J Med Virol; 2023 Jan; 95(1):e28210. PubMed ID: 36222204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Hepatocellular Carcinoma Predictive Scores PAGE-B and mPAGE-B among Brazilian Patients with Chronic Hepatitis B Virus Infection.
    Ferreira da Silva AC; Cunha-Silva M; Sevá-Pereira T; Mazo DF
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy.
    Kim SU; Seo YS; Lee HA; Kim MN; Kim EH; Kim HY; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):693-699.e1. PubMed ID: 31252188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir.
    Chang JW; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Seo YS; Lee HA; Kim MN; Lee YR; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Park SY; Kim SU
    J Viral Hepat; 2021 Jan; 28(1):95-104. PubMed ID: 33029863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment.
    Gokcen P; Guzelbulut F; Adali G; Degirmenci Salturk AG; Ozturk O; Bahadir O; Kanatsiz E; Kiyak M; Ozdil K; Doganay HL
    World J Gastroenterol; 2022 Feb; 28(6):665-674. PubMed ID: 35317422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B.
    Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
    JHEP Rep; 2021 Jun; 3(3):100290. PubMed ID: 34041470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.